Short-duration therapy for hepatitis C: Suitable for all?

Research output: Contribution to journalArticlepeer-review


Peginterferon α (PegIFN α) plus ribavirin achieves sustained virological response (SVR) in more than 50% of patients with chronic hepatitis C virus (HCV) infection. Although in the trials which led to the registration of this combination therapy, only a 48-week period of treatment had been evaluated, current international guidelines state that 48 or 24 weeks of treatment should be recommended in accordance with genotype; i.e. 48 weeks for genotypes 1 and 4, and 24 weeks for 2 and 3. However, side effects and the high cost of antiviral therapy forced investigators to evaluate further reductions in the treatment duration. Based on the new evidence that fast and persistent viral clearance is highly predictive of SVR, a week 4 negative HCV RNA by a sensitive molecular assay was recently utilized as a criterion for halving the duration of treatment to 12-16 weeks for genotypes 2 and 3, and 24 weeks for genotype 1 patients. However, some issues on this topic, are still open. In this review, existing evidence is discussed, and both the relevance and limitations of published studies are considered.

Original languageEnglish
Pages (from-to)221-227
Number of pages7
JournalJournal of Viral Hepatitis
Issue number4
Publication statusPublished - Apr 2007


  • HCV genotype
  • PegIFNα
  • Ribavirin
  • RVR

ASJC Scopus subject areas

  • Hepatology
  • Virology


Dive into the research topics of 'Short-duration therapy for hepatitis C: Suitable for all?'. Together they form a unique fingerprint.

Cite this